Select Language
Tyk2
Tyk2 Overview
| English Name | Tyrosine-protein kinase 2 | Approved Drugs | 4 |
| Drugs in Clinical Trials | 43 | Target Synonym | EC:2.7.10.2，TYK2，Tyrosine Kinase 2，Non-Receptor Tyrosine-Protein Kinase TYK2，EC 2.7.10.2，IMD35，JTK1，TYK2 Kinase，EC 2.7.10 |
| Highest Development Stage | Approved | ||
| English Name | Tyrosine-protein kinase 2 |
| Target Synonym | EC:2.7.10.2，TYK2，Tyrosine Kinase 2，Non-Receptor Tyrosine-Protein Kinase TYK2，EC 2.7.10.2，IMD35，JTK1，TYK2 Kinase，EC 2.7.10 |
| Approved Drugs | 4 |
| Drugs in Clinical Trials | 43 |
| Highest Development Stage | Approved |
Tyk2 Product List
- Product Category
Protein (2)
- Product Status
Launched (2)
- Species
Human (2)
- Tag
His Tag (2)
- Conjugate
Unconjugated (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
TY2-H5547 |  Human | InsectCells | Human Tyk2 Protein, His Tag (active enzyme) |  |  Add to Cart | ||
TY2-H5548 | Human | InsectCells | Human Tyk2 Protein, His Tag |  |  | Add to Cart |
Total: 2
- 1
Tyk2 Background
Tyk2 was the first member of the JAK family that was described (the other members are JAK1, JAK2, and JAK3). It has been implicated in IFN-α, IL-6, IL-10 and IL-12 signaling. Tyk2 functions primarily in IL-12 and type I-IFN signaling. Tyk2 deficiency has more dramatic effects in human cells than in mouse cells. However, in addition to IFN-α and -β and IL-12 signaling, Tyk2 has major effects on the transduction of IL-23, IL-10, and IL-6 signals. Recently, it has been recognized that IL-12 and IL-23 share ligand and receptor subunits that activate Tyk2. Tyk2 is activated by IL-10, and its deficiency affects the ability to generate and respond to IL-10.
Tyk2 Synonyms
Tyk2,tyrosine kinase 2
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| TLL-018 | TLL-018 | Phase 3 Clinical | Tll Pharmaceutical Llc | Arthritis, Rheumatoid; Chronic Urticaria; Colitis, Ulcerative; Dermatitis, Atopic; Lupus Erythematosus, Systemic; Plaque psoriasis; Psoriasis; Urticaria | Details |
| CMS-D001 | CMS-D001 | Phase 3 Clinical | China Medical System Holdings Ltd | Autoimmune Diseases; Dermatitis, Atopic; Plaque psoriasis; Psoriasis | Details |
| WD-890 | WD-890; WD890 | Phase 3 Clinical | Ningbo Wenda Pharma | Lupus Erythematosus, Systemic; Plaque psoriasis; Psoriasis | Details |
| BHV-8000 | TLL-041; TLL041 | Phase 3 Clinical | Hangzhou Highlightll Pharmaceutical Co Ltd | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Central Nervous System Diseases; Parkinson Disease | Details |
| Velzatinib | M-4205; IDRX-42; GSK-6042981 | Phase 3 Clinical | IDRx Inc | Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors | Details |
| Envudeucitinib | ESK-001; FTP-637 | Phase 3 Clinical | Haisco Pharmaceutical Group Co Ltd | Autoimmune Diseases; Hepatic Insufficiency; Lupus Erythematosus, Systemic; Panuveitis; Plaque psoriasis; Psoriasis; Renal Insufficiency; Uveitis, Intermediate; Uveitis, Posterior | Details |
| D-2570 | D-2570; D2570 | Phase 3 Clinical | Inventisbio Co Ltd | Arthritis, Psoriatic; Autoimmune Diseases; Colitis, Ulcerative; Lupus Erythematosus, Systemic; Plaque psoriasis; Psoriasis | Details |
| VVN-461 | VVN461LD; VVN-461; VVN461e; VVN-461-e | Phase 3 Clinical | VivaVision Biotech Inc | Dry Eye Syndromes; Inflammation; Postoperative inflammation; Uveitis; Uveitis, Anterior | Details |
| Zasocitinib | NDI-034858; TAK-279 | Phase 3 Clinical | Nimbus Therapeutics LLC | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Erythrodermic psoriasis; Generalised pustular psoriasis; Hidradenitis Suppurativa; Plaque psoriasis; Psoriasis; Vitiligo | Details |
| Quecitinib | QY201; QY-201 | Phase 3 Clinical | E-nitiate Biopharmaceuticals (Hangzhou) Co Ltd | Alopecia Areata; Arthritis, Rheumatoid; Dermatitis, Atopic; Prurigo; Prurigo Nodularis; Psoriasis; Spondylitis, Ankylosing; Vitiligo | Details |
| ICP-488 | ICP-488 | Phase 3 Clinical | InnoCare Pharma Ltd | Autoimmune Diseases; Lupus Erythematosus, Cutaneous; Plaque psoriasis; Psoriasis | Details |
| HS-10374 | HS-10374; hs 10374; hs10374; hs-10374 | Phase 3 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Alopecia Areata; Arthritis, Psoriatic; Plaque psoriasis; Psoriasis | Details |
| Soficitinib | ICP-332 | Phase 3 Clinical | InnoCare Pharma Ltd | Chronic Urticaria; Dermatitis, Atopic; Plaque psoriasis; Prurigo Nodularis; Psoriasis; Urticaria; Vitiligo | Details |
| SYHX-1901 | SYHX-1901 | Phase 3 Clinical | Cspc Ouyi Pharmaceutical Co Ltd | Alopecia Areata; Arthritis, Rheumatoid; Dermatitis, Atopic; Drug-Related Side Effects and Adverse Reactions; Hematologic Neoplasms; Lupus Erythematosus, Systemic; Plaque psoriasis; Psoriasis; Solid tumours; Vitiligo | Details |
| WXSH-0150 | WXSH-0150; TUL-01101 | Phase 2 Clinical | Zhuhai United Laboratories Co Ltd | Arthritis, Rheumatoid; Dermatitis, Atopic | Details |
| GLPG-3667 | GLPG-3667 | Phase 2 Clinical | Galapagos Nv | Dermatomyositis; Lupus Erythematosus, Systemic; Plaque psoriasis | Details |
| OST-122 | OST-122 | Phase 2 Clinical | Oncostellae Sl | Colitis, Ulcerative; Colorectal Neoplasms; Fibrosis; Inflammatory Bowel Diseases | Details |
| Ropsacitinib | PF-06826647 | Phase 2 Clinical | Pfizer Inc | Colitis, Ulcerative; Hidradenitis Suppurativa; Plaque psoriasis; Psoriasis | Details |
| Lomedeucitinib | BMS-986322 | Phase 2 Clinical | Bristol-Myers Squibb Company | Central Nervous System Diseases; Multiple Sclerosis; Psoriasis | Details |
| UA-021 | UA-021 | Phase 2 Clinical | Yousen Jianheng Biomedical (Shanghai) Co Ltd | Colitis, Ulcerative; Crohn Disease; Lupus Nephritis; Psoriasis | Details |
| TQH-3906 | TQH-3906; TQH3906 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Inflammatory Bowel Diseases; Lupus Erythematosus, Systemic; Plaque psoriasis; Psoriasis | Details |
| CS-32582 | CS-32582; CS32582 | Phase 2 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Autoimmune Diseases; Plaque psoriasis; Psoriasis | Details |
| TDM-180935 | TDM-180935 | Phase 2 Clinical | Jiaxing TechnoDerma Medicines Inc | Dermatitis, Atopic | Details |
| Cenacitinib | VTX-958 | Phase 2 Clinical | Ventyx Biosciences Inc | Arthritis, Psoriatic; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
| AC-201 | AC-201 | Phase 2 Clinical | Accro Bioscience (Suzhou) Co Ltd | Lupus Erythematosus, Systemic; Plaque psoriasis; Psoriasis; Uveitis | Details |
| ABBV-712 | ABBV-712 | Phase 1 Clinical | Abbvie Inc | Psoriasis | Details |
| GLPG-3121 | GLPG-3121 | Phase 1 Clinical | Galapagos Nv | Details | |
| A-005 | Phase 1 Clinical | Alumis Inc | Central Nervous System Infections; Encephalomyelitis; Multiple Sclerosis; Nerve Degeneration; Parkinson Disease | Details | |
| TYK2 inhibitor (BMS) | Phase 1 Clinical | Bristol-Myers Squibb Company | Autoimmune Diseases | Details | |
| ZE74-0022 | ZE74-0022 | Phase 1 Clinical | Barinthus Biotherapeutics PLC | Diabetes Mellitus, Type 1 | Details |
| NEU-627 | NEU-627 | Phase 1 Clinical | Neuron23 Inc | Multiple Sclerosis; Neuritis | Details |
| NEU-111 | NEU-111 | Phase 1 Clinical | Neuron23 Inc | Details | |
| ZG-002(Shanghai Zhi Gen) | Phase 1 Clinical | Shanghai Zhi Gen Pharmaceutical Technology Co Ltd | Plaque psoriasis | Details | |
| A-005(Alumis) | A-005(Alumis) | Phase 1 Clinical | Alumis Inc | Multiple Sclerosis; Nerve Degeneration; Neuritis; Parkinson Disease | Details |
| WD-910 | WD-910 | Phase 1 Clinical | Ningbo Wenda Pharma | Dementia; Multiple Sclerosis | Details |
| SUDO-286 | SUDO-286 | Phase 1 Clinical | Sudo Biosciences Inc | Psoriasis; Skin Diseases | Details |
| SUDO-550 | SUDO-550 | Phase 1 Clinical | Sudo Biosciences Inc | Brain Diseases; Multiple Sclerosis; Neurodegenerative Diseases | Details |
| FZ007-119 | FZ007; FZ-007 | Phase 1 Clinical | Guangzhou Fermion Technology Co Ltd | Autoimmune Diseases; Dermatitis, Atopic; Psoriasis | Details |
| ARTS-011 | ARTS-011; ARTS011 | Phase 1 Clinical | Anrui Biomedical Technology (Guangzhou) Co Ltd | Plaque psoriasis | Details |
| LNK-01006 | LNK-01006 | Phase 1 Clinical | Lynk Pharmaceutical (Hangzhou) Co Ltd | Neuroinflammatory Diseases; Solid tumours | Details |
| QY-211 | QY211; QY-211 | Phase 1 Clinical | E-nitiate Biopharmaceuticals (Hangzhou) Co Ltd | Dermatitis, Atopic; Eczema; Vitiligo | Details |
| MAX-40070 | MAX-40070; MAX-3 | Phase 1 Clinical | MaxiNovel Pharmaceuticals Co Ltd | Alopecia Areata | Details |
| BGB-23339 | BGB-23339 | Phase 1 Clinical | BeOne Medicines Ltd | Autoimmune Diseases; Plaque psoriasis | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Peficitinib | ASP-015K; JNJ-54781532 | Approved | Astellas Pharma Inc | Smyraf, 施觅福 | Japan | Arthritis, Rheumatoid | Astellas Pharma Inc | 2019-03-29 | Arthritis, Rheumatoid; Colitis, Ulcerative; Psoriasis | Details |
| Gecacitinib Hydrochloride | ZG-0128; ZG-0163 | Approved | Suzhou Zelgen Biosciences Co Ltd | 泽普平 | Mainland China | Primary Myelofibrosis | Suzhou Zelgen Biopharmaceuticals Co Ltd | 2025-05-27 | Alopecia Areata; Carcinoma, Non-Small-Cell Lung; Coronavirus Disease 2019 (COVID-19); Dermatitis, Atopic; Graft vs Host Disease; Hepatic Insufficiency; Idiopathic Pulmonary Fibrosis; Lupus Erythematosus, Systemic; Lymphoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Plaque psoriasis; Pneumonia; Polycythemia Vera; Primary Myelofibrosis; Solid tumours; Spondylitis, Ankylosing; Thrombocythemia, Essential; Vitiligo | Details |
| Deucravacitinib | BMS-986165; BMS-986165-01 | Approved | Bristol-Myers Squibb Company | Sotyktu, 颂狄多 | United States | Plaque psoriasis | Bristol-Myers Squibb Company | 2022-09-09 | Alopecia Areata; Arthritis, Juvenile; Arthritis, Psoriatic; Autoimmune Diseases; Colitis, Ulcerative; Crohn Disease; Dermatomyositis; Granuloma Annulare; Hidradenitis Suppurativa; Inflammation; Inflammatory Bowel Diseases; Lichen Planus; Liver Dysfunction; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Lupus Nephritis; Lupus Vulgaris; Myositis; Plaque psoriasis; Psoriasis; Pyoderma Gangrenosum; Renal Insufficiency; Rosacea; Sarcoidosis; Sjogren's Syndrome; Sjogren-Larsson Syndrome; Vitiligo | Details |
| Rovadicitinib | TQ-05105; CT-1995; TQ05105 | Approved | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd | 安煦, Anxu | Mainland China | Primary Myelofibrosis | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2026-02-25 | Graft vs Host Disease; Lymphohistiocytosis, Hemophagocytic; Myeloproliferative Disorders; Primary Myelofibrosis | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland